GlobeNewswire Inc | Jan 7, 2022 08:00AM EST

January 07, 2022

27 different customers representing North America and Europe

31 oral presentations across four consecutive days

Topics span the application of OGM in genetic disease and cancer research

45% of presentations are from North America and 55% are from Europe

SAN DIEGO, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr system and provider of the leading software solutions for visualization, interpretation and reporting of genomic data, today announced its Symposium lineup of 31 oral presentations delivered from 27 different customers worldwide featuring the utility of OGM across a wide range of applications for genetic disease and cancer research. In all, 45% of the customer presentations at Symposium are from North America while 55% are from Europe. Symposium will take place virtually from January 10 to 13, 2022. During these four days, customers will showcase their latest research findings using OGM in constitutional cytogenomics, hematologic malignancies, solid tumors and in combination with next-generation sequencing (NGS). Each day will feature oral customer presentations, a live panel with Q&A and a scientific poster exhibit within the virtual exhibition hall.

We believe Symposium is the quintessential event for the OGM community to come together and share the progress they are making and their ideas for expanding the utility of OGM, said Erik Holmlin, PhD, President and CEO of Bionano Genomics. Last year we were impressed by the utility, scope and breath of applications presented by our customers using the Saphyr system. Symposium is an opportunity for anyone interested or currently working with OGM to form connections within the community and see the potential impact of looking at the genome in a different way. Bionano is dedicated to elevating human health by transforming the way the world sees the genome and Im greatly looking forward to seeing our customers showcase their accomplishments with OGM at Symposium. We also plan on conducting a Symposium in China later this year to bring together our Asia Pacific customers to feature their accomplishments using OGM.

Symposium in 2021 marked a historic event where OGM users showcased their data. Since then, we have made significant improvements in OGM workflow and data analysis which have allowed our customers around the world to advance their clinical and translational research. We have seen the implementation of our Saphyr system across a broad range of clinical research applications for consolidating traditional cytogenetics workflows to OGM as well as demonstrating its utility in combination with NGS, said Alka Chaubey, PhD, FACMG, Chief Medical Officer at Bionano. Symposium attendees have an opportunity to learn from their peers and we will continue to provide our customers with the training, education and services to support our goal of making OGM the standard of care.

Each session of Symposium will start at 8:00 am PST and will last approximately 5 hours. After the scientific presentations, the speakers will join for a live panel discussion and Q&A moderated by Dr. Chaubey. In addition, each day will feature a scientific poster exhibit. Below is the list of customer presentations per day and application area.

January 10: Constitutional CytogenomicsSpeaker Institution State / Talk TitleName Country Validation of Optical Genome The Foundation for New Jersey, Mapping for PreimplantationChaim Jalas Embryonic USA Genetic Analysis ? Structural Competence Rearrangement (PGD-SR) Applications Assistance Balanced TranslocationsDr. Laila Publique?Hpitaux Associated with MaleEl-Khattabi de Paris (AP-HP) - Paris, France Infertility: How Optical Genome Universit de Paris Mapping Could Lead to New Discoveries? Clinical Utility of OpticalDr. Shirley Belfast Health and Belfast, UK Genome Mapping in aHeggarty Social Care Trust Constitutional Cytogenetics LaboratoryDr. Radboud University Nijmegen, Optical Genome Mapping: MappingAlexander Medical Center Netherlands Difficult Structural VariantHoischen Types - Repeat Expansions Validation Study of OpticalDr. Anwar University of Genome Mapping for Postnatal andIqbal Rochester Medical New York, USA Prenatal Clinical Research Center According to Established NYSDOH GuidelinesDr. Nikhil Enhanced Structural VariationSahajpal Augusta University Georgia, USA Detection with OGM in Constitutional DisordersJanuary 11: Hematologic MalignanciesSpeaker Institution State / Talk TitleName Country University Characterization of Plasma CellBence Children's Hospital Zurich, Dyscrasias (PCD) by OpticalDvorak Zurich- Eleonore Switzerland Genome Mapping Foundation The Clinical Utility of OpticalDr. Hannover Medical Hannover, Genome Mapping for theJonathan L. School Germany Assessment of GenomicLhmann Aberrations in Acute Lymphoblastic LeukemiaDr. Anna Barcelona, The Hidden Side of GenomicPuiggros Hospital del Mar Spain Complexity: Learning from OGM in Chronic Lymphocytic Leukemia Opportunities of Optical GenomeDr. Barbara University Leuven, Mapping for Genetic Diagnosis inDewaele Hospitals Leuven Belgium Acute Lymphoblastic Leukemia and Acute Myeloid LeukemiaDr. Radboud University Nijmegen, Technical and ClinicalKornelia Medical Center Netherlands Validation of Optical GenomeNeveling MappingDr. Elena Hospital Infantil Optical Genome Mapping forGarca Universitario Nio Madrid, Spain Diagnosis of PaediatricSnchez Jess Leukaemia Assessing Genomic Aberrations inDr. Brynn Columbia University New York, USA AML using Optical GenomeLevy Medical Center Mapping: Insights from a National Multi-Center Study Harvard Medical Shining a New Light on CancerDr. Adrian School Brigham and Massachusetts, Cytogenetics: Leveraging NovelDubuc Women's Hospital USA Technological Approaches for Improved Understanding in B-ALL Laboratory Medicine A Year in Review: ParallelDr. Adam C. Program, University Toronto, Testing of HematologicSmith Health Network, Canada Malignancies Using Optical University of Genome Mapping Compared to Toronto Conventional Cytogenetics Optical genome mapping: UtilityDr. Saurabh New Jersey, for stratification of B-CLL byGupta Quest Diagnostics USA accurate identification of clinically relevant structural variantsJanuary 12: Solid Tumors Speaker Institution Talk TitleNameDr. Elena Hospital Infantil Optical Genome Mapping:Garca Universitario Nio Madrid, Spain Application for Analysis ofSnchez Jess Non-Haematological CancersDr. Tuomo University of Oulu, Optical Genome Mapping inMantere Finland Oulu, Finland Unexplained High-Risk Breast Cancer FamiliesDr. UT Health - San Vigor and Reproducibility inGopalrao Antonio Texas, USA Research: The Cell Line Saga: IsVelagaleti OGM the Answer?Dr. Matthew Brigham and Women's Massachusetts, The Chromosomal Landscape ofBrian Hospital USA MesotheliomaCouger Complex Rearrangement PatternsDr. Juan Instituto de in Undifferentiated Small RoundDiaz Martin Biomedicina de Sevilla, Spain Cell Sarcomas Associated with Sevilla (IBiS) Poor Outcomes in Clinical ResearchDr. Medical College of Utility of Optical GenomeRavindra Georgia at Augusta Georgia, USA Mapping for the ChromosomalKolhe University Characterization of Solid TumorsJanuary 13: OGM + NGS Speaker Institution Talk TitleNameDr. Optical Genome Mapping:Kornelia Radboud University Nijmegen, Different Types of Hidden SV'sNeveling Medical Center Netherlands in Families with Inherited Retinal Diseases Enlightening the Dark Matter ofDr. Princess Mxima the Genome: OGM Identifies aMariangela Center for Utrecht, Germline RetrotransposonSabatella Pediatric Oncology Netherlands Insertion in SMARCB1 in Two Siblings with Atypical Teratoid Rhabdoid Tumors OGM and Capture-Based RNA-SeqDr. Gordana Children's Hospital California, Enable Comprehensive GenomicRaca Los Angeles USA Characterization of Pediatric B-lymphoblastic Leukemias Cytogenetic QC at bit.bio: How aArran bit.bio Cambridge, UK Next-Generation CytogeneticsConstantine Platform Enhances Quality Control of Next-Generation Cells Detection and Characterization of On- and Off-targetDr. Saumyaa AstraZeneca Cambridge, UK Integration of Foreign DNA inSaumyaa the Host Genomes, for Therapeutic Cell and Gene Therapy Development, Using OGM Assistance Molecular Characterization ofDr. Laila Publique?Hpitaux Genome Structural Variants inEl-Khattabi de Paris (AP-HP) - Paris, France Developmental Disorders: Universit de Paris Comparison Between OGM and Short Read WGS Combined NGS and OGM Reveal theDr. Jens University of California, Complex Structures of CircularLuebeck California, San USA Extrachromosomal DNA and other Diego Focal Amplifications in Cancer Genomes Clinical Utility of CombinedDr. Medical College of Optical Genome Mapping andRavindra Georgia at Augusta Georgia, USA Comprehensive Genomic SequencingKolhe University in Robust Evaluation of Hematological Cancers A Comprehensive Assessment of aDr. Rashmi MD Anderson Cancer Large MDS Cohort at MD AndersonKanagal Center Texas, USA Cancer Center Using OpticalShamana Genome Mapping and a Targeted NGS Panel

Symposium registration is open to all and there is no charge for attending this event. Register today at https://www.labroots.com/ms/virtual-event/bngo2022

About Bionano Genomics

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Companys mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit www.bionanogenomics.com, www.lineagen.com or www.biodiscovery.com

Forward-Looking Statements of Bionano Genomics

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the anticipated benefits of the Symposium, our plans to conduct a Symposium in China later this year, and the potential for OGM to become the standard of care. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape, including the introduction of competitive technologies or improvements in existing technologies; failure of future study results to support those demonstrated during the presentations referenced in this press release; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated withour business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2020 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on managements assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com

Investor Relations:Amy ConradJuniper Point+1 (858) 366-3243amy@juniper-point.com

Media Relations:Michael SullivanSeismic+1 (503) 799-7520michael@teamseismic.com